Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Events


The cardiac abnormalities in patients with cirrhosis are already reported from the 50's, in studies of patients with alcoholic cirrhosis. Further studies have shown that these cardiac changes were caused not only by the myotoxic effects of alcohol, but also are present in many patients regardless of etiology of cirrhosis. These changes are characterized by abnormalities of systolic contraction in patients undergoing physical or pharmacological stress, changes in diastolic function and electrophysiological changes in a clinical condition known as cirrhotic cardiomyopathy. Increased QT interval and the pre-ejection time changes are common in cirrhotic patients. To date no studies have evaluated the clinical relevance of changes in the heart of cirrhotic patients, or their relationship with the prognosis of affected patients. Til now, researches are based on strict echocardiographic parameters, not including several modern methods of assessment of cardiac systole and diastole. New techniques, such as two-dimensional strain, can bring new diagnostic and prognostic information, and it is not reported in the literature. Therefore, the aim of this study is to determine the morphological and functional cardiac changes in patients with cirrhosis and their prognostic role by evaluating new echocardiographic parameters of systolic and diastolic readings.

Full Title of Study: “Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Adverse Events”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective

Arms, Groups and Cohorts

  • Child A liver cirrhosis
  • Child B liver cirrhosis
  • Child C liver cirrhosis

Clinical Trial Outcome Measures

Primary Measures

  • Adverse events as defined as composite of death due to liver failure, gastrointestinal bleeding, spontaneous bacterial peritonitis or need to conduct liver transplant in patients with liver cirrhosis.
    • Time Frame: 12 months follow-up
    • Identify the occurrence of adverse events as defined as: death due to liver failure, characterized by development of severe liver injury with impaired synthetic function and encephalopathy in a person who previously had well-compensated liver disease. either upper or lower gastrointestinal bleeding, characterized by hematemesis (vomiting of blood or coffee-ground like material) and/or melena (black, tarry stools). spontaneous bacterial peritonitis, characterized by as an ascitic fluid infection without an evident intraabdominal surgically-treatable source. liver transplant.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with cirrhosis of any etiology, diagnosed by clinical criteria and ultrasound and / or liver biopsy, which excluded patients with causes that also may affect cardiac function (hemochromatosis, Wilson disease, amyloidosis). – Age between 18 and 80 years. – Signing of written informed consent. Exclusion Criteria:

  • History or presence of systemic arterial hypertension (treated or not) – History or presence of ischemic heart disease and peripheral vascular disease. – Presence of greater than mild valvular disease. – Patients who have a different rhythm in the baseline electrocardiogram, other than sinus (atrial fibrillation, atrial flutter, junctional rhythm). – Presence of severe anemia (Hb <7 g / dL). – Presence of shock, hepatic encephalopathy, bacterial infection or bleeding at inclusion or during the previous week. – History or presence of severe or decompensated lung disease. – Presence of percutaneous intrahepatic porto-systemic shunt (TIPS). – Pregnancy.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rio de Janeiro State University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Angelo Antunes Salgado, Clinical practitioner – Rio de Janeiro State University
  • Overall Official(s)
    • Angelo A Salgado, Master, Principal Investigator, Rio de Janeiro State University
    • Carlos Terra, PHD, Study Chair, Rio de Janeiro State University
    • M├írcia B Castier, PHD, Study Chair, Rio de Janeiro State University
    • Paulo R Benchimol-Barbosa, DSC, Study Chair, Rio de Janeiro State University
    • Camila SS Reis, MD, Principal Investigator, Universidade de Estado do Rio de Janeiro

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.